Cargando…

Protein production is an early biomarker for RNA‐targeted therapies

OBJECTIVES: Clinical trials for progressive neurodegenerative disorders such as Alzheimer's Disease and Amyotrophic Lateral Sclerosis have been hindered due to the absence of effective pharmacodynamics markers to assay target engagement. We tested whether measurements of new protein production...

Descripción completa

Detalles Bibliográficos
Autores principales:	Self, Wade K., Schoch, Kathleen M., Alex, Jacob, Barthélemy, Nicolas, Bollinger, James G., Sato, Chihiro, Cole, Tracy, Kordasiewicz, Holly B., Swayze, Eric, Bateman, Randall J., Miller, Timothy M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292185/ https://www.ncbi.nlm.nih.gov/pubmed/30564616 http://dx.doi.org/10.1002/acn3.657

Ejemplares similares

2342 Protein production as an early pharmacodynamics biomarker for RNA-targeting therapies
por: Self, Wade K., et al.
Publicado: (2018)

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer’s Disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2019)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction
por: Ezerskiy, Lubov A., et al.
Publicado: (2022)

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
por: Janelidze, Shorena, et al.
Publicado: (2023)

Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain
por: Horie, Kanta, et al.
Publicado: (2020)

Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system
por: Sullivan, Jenna M., et al.
Publicado: (2020)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2017)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

Protein kinetics of superoxide dismutase‐1 in familial and sporadic amyotrophic lateral sclerosis
por: Ly, Cindy V., et al.
Publicado: (2023)

MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology
por: Sato, Chihiro, et al.
Publicado: (2021)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Application of unmanned aerial system structure from motion point cloud detected tree heights and stem diameters to model missing stem diameters
por: Swayze, Neal C., et al.
Publicado: (2022)

Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
por: Østergaard, Michael E., et al.
Publicado: (2013)

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
por: Cole, Tracy A., et al.
Publicado: (2021)

The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration
por: Jafar-nejad, Paymaan, et al.
Publicado: (2020)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement
por: Poplawski, Shane G., et al.
Publicado: (2020)

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
por: Horie, Kanta, et al.
Publicado: (2023)

Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease
por: Salvadó, Gemma, et al.
Publicado: (2023)

Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
por: Skotte, Niels H., et al.
Publicado: (2014)

Diurnal oscillation of CSF Aβ and other AD biomarkers
por: Lucey, Brendan P., et al.
Publicado: (2017)

Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial
por: Delrieu, Julien, et al.
Publicado: (2023)

Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer’s Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated
por: Barthélemy, Nicolas R., et al.
Publicado: (2022)

Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
por: Tosun, Duygu, et al.
Publicado: (2021)

A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer’s disease
por: Budelier, Melissa M., et al.
Publicado: (2022)

Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery
por: Yoon, Hyejin, et al.
Publicado: (2017)

Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment
por: O’Callaghan, Brennon, et al.
Publicado: (2020)

The influence of income and testosterone on the validity of facial width-to-height ratio as a biomarker for dominance
por: Noser, Emilou, et al.
Publicado: (2018)

Antisense oligonucleotides extend survival of prion-infected mice
por: Raymond, Gregory J., et al.
Publicado: (2019)

CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
por: Horie, Kanta, et al.
Publicado: (2022)

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
por: McDade, Eric, et al.
Publicado: (2022)

The column procedure preserves elbow stability on biomechanical testing
por: Podgórski, Andrzej P., et al.
Publicado: (2020)

Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides
por: Reidenbach, Andrew G., et al.
Publicado: (2019)

Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice
por: Iyer, Abhirami K., et al.
Publicado: (2023)

Macroscopic and ultrasonographic anatomy of the rotator cuff layers
por: Czyrny, Zbigniew, et al.
Publicado: (2019)

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018)

An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS
por: Self, Wade, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jupoh048aujadot166stc3nt3p